Eosinophil and Cationic Protein Levels in Patients Treated With Dupilumab: A Real-Life Study.
作者信息
Castillo María Alejandra, Correa-Borit Jorge, Laorden Daniel, Adrianzen Fiorella, Villamañán Elena, Romero David, Quirce Santiago, Domínguez-Ortega Javier
机构信息
Department of Pneumology, La Paz University Hospital, Madrid, Spain.
Department of Allergy, La Paz University Hospital, Madrid, Spain.
出版信息
Open Respir Arch. 2025 May 17;7(3):100444. doi: 10.1016/j.opresp.2025.100444. eCollection 2025 Jul-Sep.
Abstract
摘要
相似文献
1
Eosinophil and Cationic Protein Levels in Patients Treated With Dupilumab: A Real-Life Study.
Open Respir Arch. 2025 May 17;7(3):100444. doi: 10.1016/j.opresp.2025.100444. eCollection 2025 Jul-Sep.
2
Real-world Effectiveness of Dupilumab in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis.
J Clin Gastroenterol. 2025 Jul 1;59(6):483-490. doi: 10.1097/MCG.0000000000002146.
3
Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab.
JAMA Dermatol. 2025 Jun 18. doi: 10.1001/jamadermatol.2025.1578.
4
Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV) in Uncontrolled Moderate-To-Severe Asthma.
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1370-1380. doi: 10.1002/psp4.70057. Epub 2025 Jun 19.
5
Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy.
Cureus. 2025 May 16;17(5):e84252. doi: 10.7759/cureus.84252. eCollection 2025 May.
6
Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
Eur Respir J. 2025 Jun 19. doi: 10.1183/13993003.00139-2025.
7
Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.
Am J Gastroenterol. 2025 Jun 18. doi: 10.14309/ajg.0000000000003599.
8
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.
Life (Basel). 2023 Sep 8;13(9):1884. doi: 10.3390/life13091884.
9
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
J Clin Aesthet Dermatol. 2025 May 1;18(5):16-19.
10
Neonatal necrotizing enterocolitis attenuates adult asthma via eosinophil ferroptosis.
Cell Signal. 2025 Sep;133:111878. doi: 10.1016/j.cellsig.2025.111878. Epub 2025 May 16.
本文引用的文献
1
The value of biomarkers in the therapy of CRSwNP with biologicals-a long-term follow-up of dupilumab therapy.
Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4789-4805. doi: 10.1007/s00405-024-08574-4. Epub 2024 May 6.
2
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
Biomedicines. 2024 Feb 8;12(2):390. doi: 10.3390/biomedicines12020390.
3
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.
Life (Basel). 2023 Sep 8;13(9):1884. doi: 10.3390/life13091884.
4
[Consensus document for severe asthma in adults. 2022 update].
Open Respir Arch. 2022 Jul 2;4(3):100192. doi: 10.1016/j.opresp.2022.100192. eCollection 2022 Jul-Sep.
5
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
Allergy. 2023 Oct;78(10):2669-2683. doi: 10.1111/all.15772. Epub 2023 May 26.
6
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Front Immunol. 2023 Mar 30;14:1121237. doi: 10.3389/fimmu.2023.1121237. eCollection 2023.
7
Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma.
ERJ Open Res. 2022 Sep 26;8(3). doi: 10.1183/23120541.00138-2022. eCollection 2022 Jul.
8
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management.
Expert Rev Respir Med. 2022 Jul;16(7):713-721. doi: 10.1080/17476348.2022.2090342. Epub 2022 Jun 23.
9
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28.
10
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Expert Rev Clin Immunol. 2020 Dec;16(12):1115-1125. doi: 10.1080/1744666X.2021.1847083. Epub 2020 Nov 15.
Zotero 插件